Capricor Therapeutics CAPR Increase Decrease From Grants Receivable
Increase Decrease From Grants Receivable at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept capr:IncreaseDecreaseFromGrantsReceivable.
The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Capricor Therapeutics's increase decrease from grants receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Capricor Therapeutics's increase decrease from grants receivable?
- Capricor Therapeutics (CAPR) reported increase decrease from grants receivable of -$59.17K in Q1 2026.
- How has Capricor Therapeutics's increase decrease from grants receivable changed year-over-year?
- Capricor Therapeutics's increase decrease from grants receivable increased by 99.4% year-over-year, from -$10.31M to -$59.17K.
- What does increase decrease from grants receivable mean?
- This metric tracks the change in funds owed to the company by grant-issuing organizations for research and development activities. An increase in this balance indicates that the company has recognized revenue or incurred expenses that are reimbursable but not yet collected in cash. It is a critical indicator of the timing of cash inflows from non-dilutive funding sources.